1 (1203dd0c 809a 4409 B948 B5e816b8a63a 01)
Alendronate Sodium Tablet
Product Images NDC 68071-3771
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 68071-3771). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
2 (1203dd0c 809a 4409 B948 B5e816b8a63a 02)
This document provides data on the cumulative incidence of hip fractures in a three-year study. It compares the results between patients with radiographic vertebral fractures at baseline who received a placebo versus those who were treated with alendronate sodium. The information is presented graphically over the course of the study in terms of months.*
3 (1203dd0c 809a 4409 B948 B5e816b8a63a 03)
This text provides information about osteoporosis treatment studies in postmenopausal women, specifically focusing on the increase in bone mineral density (BMD) with Alendronate Sodium 10mg/day at three years. The data appears to include measurements for the lumbar spine, femoral neck, and trochanter.*
4 (1203dd0c 809a 4409 B948 B5e816b8a63a 04)
5 (1203dd0c 809a 4409 B948 B5e816b8a63a 05)
This text appears to show data related to changes in Bone Mineral Density (BMD) in postmenopausal women over 2-year and 3-year studies focusing on osteoporosis prevention. The table likely indicates the mean percentage change (+SE) in BMD from baseline at different bone sites such as lumbar spine, femoral neck, trochanter, and total body. The specific values for the BMD changes are not provided in the provided passage.*
6 (1203dd0c 809a 4409 B948 B5e816b8a63a 06)
7 (1203dd0c 809a 4409 B948 B5e816b8a63a 07)
This text discusses a study on Paget's Disease of Bone investigating the effects of Alendronate Sodium 40mg/day compared to a placebo or Etidronate 400mg/day on serum alkaline phosphatase levels. The study involved a total of 27 participants. The results are presented in a graph showing the mean percentage change from baseline over time in months. Results from both an international study and a U.S. study are compared in the graph.*
Pdp (68071 3771 5)
This is a label of Alendronate Sodium 70mg Tablets from Care Pharmaceuticals, Inc. It contains important information such as lot number, expiration date, ingredients, serial number, and instructions on storage. It also warns to keep the medication out of reach of children and store at a controlled temperature. Customers are advised to contact their doctor for medical advice and report side effects to FDA.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
